The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374 on June 26, 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the impact factor is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Other journal metrics for JITC can be found on the journal website.
JITC seeks submissions to its Basic Tumor Immunology section
Edited by Cornelis J.M. Melief, MD, PhD, the Basic Tumor Immunology section publishes on topics that include Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Submit your manuscript today to the open access journal.
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this $2,400 value member benefit, contact SITC at +1 414-271-2456 or JITCEditor@sitcancer.org for your member code prior to submission.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
CD8+ T lymphocytes are the major anti-tumor effector cells. Most cancer immunotherapeutic approaches seek to amplify cytotoxic T lymphocytes (CTL) specific to malignant cells. A recently identified subpopulation of memory CD8+ T cells, named tissue-resident memory T (TRM) cells, persists in peripheral tissues and does not recirculate. This T-cell subset is considered an independent memory T-cell lineage with a specific profile of transcription factors, including Runx3+, Notch+, Hobit+, Blimp1+, BATF+, AHR+, EOMESneg and Tbetlow...
Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress response encompasses a broad set of physiological changes that have evolved to safeguard the host following major tissue trauma. These stress responses, however, intersect with cellular mediators and signaling pathways that contribute to cancer proliferation...
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy’ to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization...
The Cancer Center at Beth Israel Deaconess Medical Center will present two events focused on cancer immunotherapy in the month of October. All are invited. Standard of Cure Cancer Symposium, October 17 ...
Following the recent announcement of the Venue for Global Conference on Cancer & Oncology Research The World Cancer Congress 2019 will now be held in Dubai, at the Radisson Blu Hotel, Dubai Waterfront on 04-05 March 2019 For any enquiries regarding ...
This message was posted by a user wishing to remain anonymous October 26-27, 2018 Zuckerman Research Center New York City Systemic anticancer therapies including cytotoxic chemotherapies, targeted therapies, and immunotherapies have resulted ...
We extended our deadline for early-bird passes to World Cancer Congress 2019 , which takes place on March 04-05, but your chance to save up to $100 is rapidly slipping away. In just one day - that's September 28 at midnight PST - the early bird ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org